Organization
The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China
35 abstracts
Abstract
Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study.Org: Shanxi Provincial People’s Hospital, Xi'an, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sichuan Cancer Hospital & Institute, Sichuan, Cancer Center, Chengdu, China,
Abstract
First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.Org: Fujian Cancer Hospital, First Chest Radiotherapy Department, Hunan Cancer Hospital, Changsha, China, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China, Department of Melanoma Oncology, The Third People's Hospital of Zhengzhou, Zhengzhou, China, The Third People's Hospital of Zhengzhou,
Abstract
A machine learning–based radiomics approach to predict MUC4 mutation and response to immunotherapy in cholangiocarcinoma.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, The Second Affiliated Hospital, Fujian Medical University, Quanzhou, China, First Affiliated Hospital of Zhejiang University School of Medicine,
Abstract
Efficacy and safety of envafolimab plus lenvatinib combined with TACE in initially unresectable hepatocellular carcinoma: An open-label, single-arm, phase II study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, First Hospital of Jilin University, Changchun, China,
Abstract
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy.Org: Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Zhejiang University, Hangzhou, China,
Abstract
Efficacy and safety of ruxolitinib in patients with lower risk myelofibrosis: A single-arm, exploratory and prospective study.Org: The First Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang University, Hangzhou, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine,
Abstract
Comparative efficacy of systemic sequential regorafenib after TACE combined with first-line targeted drugs (donafenib, sorafenib, or lenvatinib) after treatment failure for advanced hepatocellular carcinoma: A retrospective, single-center, real-world study.Org: University of Science and Technology of China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Hefei, China,
Abstract
Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Differential IDH1 and IDH2 mutation-related landscape in intrahepatic cholangiocarcinoma.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, First Affiliated Hospital of Zhejiang University School of Medicine,
Abstract
Identifying intra-abdominal desmoid type fibromatosis mimicking recurrence/metastasis of GISTs using FAPI PET/CT.Org: University Medical Center Groningen, University of Groningen, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, The First Affiliated Hospital of Sun Yat-sen University, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Integrating pathomics and radiomics for predicting survival among patients with intrahepatic cholangiocarcinoma undergoing surgical resection.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group,
Abstract
Correlation between imatinib trough concentration and efficacy in patients with advanced GIST with different genotypes.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sun Yat-sen University Cancer Center Gansu Hospital, Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.Org: Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China, Women's Hospital School of Medicine Zhejiang University,
Abstract
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, The Second Affiliated Hospital of Xi'an Jiaotong University,
Abstract
Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,
Abstract
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.Org: Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,
Abstract
Comparison of characteristics and prognostic impact of FUS-ERG and AML1-MTG16 fusion genes in adult AML patients: A retrospective study from 1988 to 2022 with a medical database.Org: Zhejiang University, Hangzhou, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, First Affiliated Hospital of Wannan Medical College, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China,
Abstract
Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world study.Org: Southeast University, Zhongda Hospital, Southeast University, Tumor Hospital Affiliated to Nantong University, Jiangsu Cancer Hopital, Xuzhou Central Hospital,
Abstract
A phase 2 study of HLX208, a BRAFV600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harboring BRAFV600E mutation.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, West China Hospital of Sichuan University, Zhongshan Hospital of Fudan University, Shanghai, China, Huashan Hospital Fudan University, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China,
Abstract
A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non–small-cell lung cancer (NSCLC) harboring uncommon EGFR mutations.Org: Shanghai Pulmonary Hospital, Shanghai, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Bengbu Medical College, Shanghai Chest Hospital, Jiaotong University,
Abstract
Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi‑center, randomized, open‑label trial.Org: Women's Hospital School of Medicine Zhejiang University, Qilu Hospital of Shandong University, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Second University Hospital,
Abstract
Modulating MDSCs by HF1K16: A mono-therapy phase Ia study examining safety and preliminary efficacy in patients with refractory and metastatic cancer.Org: Hangzhou Highfield Biopharmaceuticals Inc., Zhejiang University, School of Pharmacy, Hua Shan Hospital, Department of Clinical Pharmacy & Pharmacology, UMCG, Groningen, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China,
Abstract
Combination targeted therapy with avapritinib and sunitinib in patients with refractory gastrointestinal stromal tumors after failure of standard treatments: A small prospective pilot study.Org: The First Affiliated Hospital of Sun Yat-sen University, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Dept of GI Surgery, The Affiliated Hospital, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,
Abstract
Jaktinib in patients (pts) with myelofibrosis (MF) who were refractory to or relapsed after ruxolitinib: A single-arm, open-label, multicenter, phase 2 study.Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou Yirui Pharmaceutical Technology, China National Biotec Group,
Abstract
Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Harbin Medical University Cancer Hospital, Xuzhou Central Hospital, Xuzhou, China, The First Hospital of China Medical University, Shenyang, China,
Abstract
Identification of a novel NPM1 mutation in acute myeloid leukemia.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China, Hangzhou, China, Hangzhou, Zhejiang, China,
Abstract
Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC.Org: Department of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China,
Abstract
The safety and efficacy of donafenib combined with anti-PD-1 antibody as adjuvant therapy for patients (pts) with hepatocellular carcinoma (HCC): Updated results of a phase 2 study.Org: Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou, China, Zhejiang, China,
Abstract
Risk factors for lymph node metastasis and clinical outcomes in cervical cancer patients following primary radical hysterectomy: A single-center analysis of 1495 patients.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Division of Life Sciences and Medicine, University of Science and Technology of China, University of Science and Technology of China, Hefei, Anhui, China,
Abstract
Clinical safety and efficacy observation of ex vivo-expanded peripheral blood-derived allogeneic NK cells in the treatment of refractory or recurrent ovarian cancer.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Division of Life Sciences and Medicine, University of Science and Technology of China, Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Shanghai NK CellTech Co. Ltd,
Abstract
Respiratory toxicities after concurrent chemoradiotherapy and subsequent consolidation immune checkpoint inhibitors in locally advanced non-small cell lung cancer: Infectious and non-infectious subtypes by pathogen NGS testing.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Department of Cardiac Surgery, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China,
Abstract
A cross-sectional study of 73,390 women without ovarian cancer and the effect of age and benign gynecological diseases on serum CA125 levels.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, University of Science and Technology of China, Provincial Hospital Affiliated to Anhui Medical University, CAS Key Laboratory of Innate Immunity and Chronic Disease, Institute of Public Health Sciences,
Abstract
Ripretinib therapy in treating advanced gastrointestinal stromal tumors: A single-center analysis in a real-world setting.Org: The First Affiliated Hospital of Sun Yat-sen University, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, The Seventh Affiliated Hospital of SunYat-sen University,
Abstract
CD57+CD8+ T cells and response to PD-1/PD-L1 blockade in patients with NSCLC.Org: Department of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China,